FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003095957> ?p ?o ?g. }

• W2003095957 endingPage "192" @default.
• W2003095957 startingPage "186" @default.
• W2003095957 abstract "To describe the incidence of and risk factors for visual acuity (VA) loss and ocular complications in patients with juvenile idiopathic arthritis (JIA)-associated uveitis.Multicenter retrospective cohort study.A total of 327 patients (596 affected eyes) with JIA-associated uveitis managed at 5 tertiary uveitis clinics in the United States.Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study. Demographic and clinical characteristics were obtained for every eye of every patient at every visit via medical record review by trained expert reviewers.Loss of VA to 20/50 or to 20/200 or worse thresholds and the development of ocular complications.At presentation, 240 eyes (40.3%) had a VA of ≤20/50, 144 eyes (24.2%) had a VA of ≤20/200, and 359 eyes (60.2%) had at least 1 ocular complication. The incidences of VA loss to the ≤20/50 and ≤20/200 thresholds were 0.18 and 0.09 per eye-year (EY), respectively; the incidence of developing at least 1 new ocular complication over follow-up was 0.15/EY (95% confidence interval [CI], 0.13-0.17). However, among eyes with uveitis that had no complications at presentation, the rate of developing at least 1 ocular complication during follow-up was lower (0.04/EY; 95% CI, 0.02-0.06). Posterior synechiae, active uveitis, and prior intraocular surgery were statistically significantly associated with VA to the ≤20/50 and ≤20/200 thresholds both at presentation and during follow-up. Increasing (time-updated) anterior chamber cell grade was associated with increased rates of visual loss in a dose-dependent fashion. Use of immunosuppressive drugs was associated with a reduced risk of visual loss, particularly for the ≤20/50 outcome (hazard ratio, 0.40; 95% CI, 0.21-0.75; P<0.01).Ocular complications and vision loss were common in our cohort. Increasing uveitis activity was associated with increased risk of vision loss, and use of immunosuppressive drugs was associated with reduced risk of vision loss, suggesting that control of inflammation and use of immunosuppression may be critical aspects in improving the outcomes of patients with JIA-related uveitis.The author(s) have no proprietary or commercial interest in any materials discussed in this article." @default.
• W2003095957 created "2016-06-24" @default.
• W2003095957 creator A5006274430 @default.
• W2003095957 creator A5012888712 @default.
• W2003095957 creator A5016920591 @default.
• W2003095957 creator A5022396471 @default.
• W2003095957 creator A5041124754 @default.
• W2003095957 creator A5051180440 @default.
• W2003095957 creator A5056253720 @default.
• W2003095957 creator A5062040591 @default.
• W2003095957 creator A5062196360 @default.
• W2003095957 creator A5073077641 @default.
• W2003095957 creator A5082563606 @default.
• W2003095957 date "2013-01-01" @default.
• W2003095957 modified "2023-10-16" @default.
• W2003095957 title "Risk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Study" @default.
• W2003095957 cites W1607801679 @default.
• W2003095957 cites W1965637306 @default.
• W2003095957 cites W1974162532 @default.
• W2003095957 cites W1981916648 @default.
• W2003095957 cites W1996117162 @default.
• W2003095957 cites W1997485798 @default.
• W2003095957 cites W2012658469 @default.
• W2003095957 cites W2014114774 @default.
• W2003095957 cites W2026992146 @default.
• W2003095957 cites W2027090790 @default.
• W2003095957 cites W2035244366 @default.
• W2003095957 cites W2036644487 @default.
• W2003095957 cites W2039468792 @default.
• W2003095957 cites W2045952946 @default.
• W2003095957 cites W2050695305 @default.
• W2003095957 cites W2053136050 @default.
• W2003095957 cites W2055913604 @default.
• W2003095957 cites W2058208326 @default.
• W2003095957 cites W2058660748 @default.
• W2003095957 cites W2061198727 @default.
• W2003095957 cites W2062170681 @default.
• W2003095957 cites W2064325706 @default.
• W2003095957 cites W2071008401 @default.
• W2003095957 cites W2073127781 @default.
• W2003095957 cites W2102631597 @default.
• W2003095957 cites W2111099332 @default.
• W2003095957 cites W2112901522 @default.
• W2003095957 cites W2116724316 @default.
• W2003095957 cites W2119333176 @default.
• W2003095957 cites W2139499737 @default.
• W2003095957 cites W2149191255 @default.
• W2003095957 cites W2156308487 @default.
• W2003095957 cites W2157110439 @default.
• W2003095957 cites W2168908756 @default.
• W2003095957 cites W2245147092 @default.
• W2003095957 cites W4206228721 @default.
• W2003095957 doi "https://doi.org/10.1016/j.ophtha.2012.07.052" @default.
• W2003095957 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3536914" @default.
• W2003095957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23062650" @default.
• W2003095957 hasPublicationYear "2013" @default.
• W2003095957 type Work @default.
• W2003095957 sameAs 2003095957 @default.
• W2003095957 citedByCount "143" @default.
• W2003095957 countsByYear W20030959572013 @default.
• W2003095957 countsByYear W20030959572014 @default.
• W2003095957 countsByYear W20030959572015 @default.
• W2003095957 countsByYear W20030959572016 @default.
• W2003095957 countsByYear W20030959572017 @default.
• W2003095957 countsByYear W20030959572018 @default.
• W2003095957 countsByYear W20030959572019 @default.
• W2003095957 countsByYear W20030959572020 @default.
• W2003095957 countsByYear W20030959572021 @default.
• W2003095957 countsByYear W20030959572022 @default.
• W2003095957 countsByYear W20030959572023 @default.
• W2003095957 crossrefType "journal-article" @default.
• W2003095957 hasAuthorship W2003095957A5006274430 @default.
• W2003095957 hasAuthorship W2003095957A5012888712 @default.
• W2003095957 hasAuthorship W2003095957A5016920591 @default.
• W2003095957 hasAuthorship W2003095957A5022396471 @default.
• W2003095957 hasAuthorship W2003095957A5041124754 @default.
• W2003095957 hasAuthorship W2003095957A5051180440 @default.
• W2003095957 hasAuthorship W2003095957A5056253720 @default.
• W2003095957 hasAuthorship W2003095957A5062040591 @default.
• W2003095957 hasAuthorship W2003095957A5062196360 @default.
• W2003095957 hasAuthorship W2003095957A5073077641 @default.
• W2003095957 hasAuthorship W2003095957A5082563606 @default.
• W2003095957 hasBestOaLocation W20030959572 @default.
• W2003095957 hasConcept C118487528 @default.
• W2003095957 hasConcept C120665830 @default.
• W2003095957 hasConcept C121332964 @default.
• W2003095957 hasConcept C126322002 @default.
• W2003095957 hasConcept C141071460 @default.
• W2003095957 hasConcept C167135981 @default.
• W2003095957 hasConcept C201903717 @default.
• W2003095957 hasConcept C2776194053 @default.
• W2003095957 hasConcept C2777077863 @default.
• W2003095957 hasConcept C2778257484 @default.
• W2003095957 hasConcept C61511704 @default.
• W2003095957 hasConcept C71924100 @default.
• W2003095957 hasConcept C72563966 @default.
• W2003095957 hasConcept C81182388 @default.
• W2003095957 hasConceptScore W2003095957C118487528 @default.

• next